Clinical Validation of Unani Pharmacopoeial Formulation Majoon Suparipak in Sayalān Al-Rahim (Leucorrhoea)

Abstract

Leucorrhoea is a broad term commonly used for a condition where woman suffer from uterine, cervical or vaginal discharge other than blood due to genital tract infection or alteration in genital physiology and is highly prevalent (31–70%). In Unani medical literature it is described as Sayalān al-Rahim. According to Avicenna, uterus contains excessive waste products and hence prone to infection which leads to weakening of digestive faculty of uterine vessels resulting in discharge. The purpose of the present study was to validate the safety and efficacy of Unani pharmacopoeial formulation Majoon Suparipak in leucorrhoea. This open label validation study conducted on 103 eligible women were randomly enrolled and given Majoon Suparipak at a dosage of 7 g twice a day for four weeks. The levels of improvement were recorded at 14^th day and at the end of the study, in terms of percentage efficacy as calculated from improvement in the sign and symptoms in the visual analogue scale. The baseline and follow up values were statistically analyzed using Friedman post-hoc test and Student’s paired ‘t’ test. The result was expressed as Mean ± SEM. The amount of vaginal discharge, backache, general weakness and anaemia were significantly improved (P<0.01). The present study gives the impression that a Unani pharmacopoeial formulation Majoon Suparipak improves the general health, targets the causative agents of the disease and helps in effective management of leucorrhoea.